Nuwellis, Inc. (NUWE)
NASDAQ: NUWE · IEX Real-Time Price · USD
0.672
+0.044 (7.05%)
Nov 30, 2023, 12:20 PM EST - Market open
Nuwellis Revenue
Nuwellis had revenue of $8.65M in the twelve months ending September 30, 2023, with 10.27% growth year-over-year. Revenue in the quarter ending September 30, 2023 was $2.41M with 16.80% year-over-year growth. In the year 2022, Nuwellis had annual revenue of $8.54M with 7.85% growth.
Revenue (ttm)
$8.65M
Revenue Growth
+10.27%
P/S Ratio
0.24
Revenue / Employee
$123,600
Employees
70
Market Cap
2.15M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 8.54M | 622.00K | 7.85% |
Dec 31, 2021 | 7.92M | 480.00K | 6.45% |
Dec 31, 2020 | 7.44M | 1.93M | 35.02% |
Dec 31, 2019 | 5.51M | 513.00K | 10.26% |
Dec 31, 2018 | 5.00M | 1.45M | 40.67% |
Dec 31, 2017 | 3.55M | 2.26M | 175.64% |
Dec 31, 2016 | 1.29M | 1.23M | 2,084.75% |
Dec 31, 2015 | 59.00K | -236.00K | -80.00% |
Dec 31, 2014 | 295.00K | 236.00K | 400.00% |
Dec 31, 2013 | 59.00K | - | - |
Dec 31, 2012 | 0 | - | - |
Dec 31, 2011 | 0 | - | - |
Dec 31, 2010 | 407.00K | 183.00K | 81.70% |
Dec 31, 2009 | 224.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Dynatronics | 37.91M |
Sonoma Pharmaceuticals | 12.12M |
Motus GI Holdings | 364.00K |
Nexalin Technology | 128.64K |
Aclarion | 84.13K |
NUWE News
- 15 days ago - Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 23 days ago - Nuwellis, Inc. Announces Third Quarter 2023 Financial Results - GlobeNewsWire
- 6 weeks ago - Nuwellis, Inc. To Announce Third Quarter 2023 Financial Results on November 7, 2023 - GlobeNewsWire
- 6 weeks ago - Nuwellis Announces Closing of $2.25 Million Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants - GlobeNewsWire
- 6 weeks ago - Nuwellis Announces Pricing of $2.25 Million Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants - GlobeNewsWire
- 7 weeks ago - Nuwellis Provides Regulatory Update on SeaStar Medical's Selective Cytopheretic Device Use in Pediatric Acute Kidney Injury Under a Humanitarian Device Exemption - GlobeNewsWire
- 2 months ago - Nuwellis to Present at the Gilmartin Group Emerging Growth Showcase - GlobeNewsWire
- 4 months ago - Nuwellis, Inc. Announces Second Quarter 2023 Financial Results - GlobeNewsWire